Team

Øystein Soug

Chief Executive Officer

Ramzi Amri

Chief Financial Officer

Zuzana Jiráková Trnková

Chief Medical Officer

Gro Hjellum

Chief Operating Officer

Kristine Lofthus

Chief Production Officer

Sara Westrøm

Chief Scientific Officer

Anne-Kirsti Aksnes

Chief Clinical Officer

Anne Cecilie Alvik

Head of Quality Assurance

Kaja Tunhøvd Johansen

Head of Quality Control

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.

Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997

Ramzi Amri

Chief Financial Officer

Dr. Amri joins Oncoinvent from Galapagos NV, where he most recently served as Vice President and Head of Development Strategy & Execution. He brings broad international experience through leadership positions in strategy, operations, and corporate transformation across the life sciences and healthcare industries. Dr. Amri also brings seven years of management consulting experience from McKinsey & Company, advising global pharma and biotech clients, as well as financial institutions and private-equity-backed businesses, on growth, M&A, and organizational transformation.

Dr. Amri holds an M.D. and a Ph.D. from the University of Amsterdam. He conducted his Ph.D. research and completed a postdoctoral fellowship in surgical oncology and epidemiology at Harvard Medical School and Massachusetts General Hospital, where he initiated and led a research program in colorectal cancer.

Zuzana Jiráková Trnková

Chief Medical Officer

Dr. Zuzana Jiráková Trnková is a physician-scientist with more than 20 years of clinical development experience in global pharmaceutical and biotech companies. Most recently, she served as Chief Medical Officer of Highlight Therapeutics, a clinical-stage immuno-oncology company. Prior to this, she was Vice President, Head of Medical Affairs and Clinical Development Radiology at Bayer and a member of Bayer’s Global Leadership Circle. From 2017 to 2020, she was Vice President Clinical Research and Development at BioNTech, reporting to co-founders Prof. Uğur Şahin and Prof. Özlem Türeci. She spent the preceding decade at Bayer, including as Vice President, Head of Clinical Pharmacology Oncology, supporting a portfolio that included radium-223 (Xofigo®), the thorium platform, regorafenib and ADCs. Earlier, she led two global pivotal Phase III trials resulting in the approval of Gadovist® for breast cancer detection. Dr. Jiráková Trnková holds an MD and a PhD in immunology and molecular biology from Charles University in Prague.

.

Gro Hjellum

Chief Operating Officer

hjellum@oncoinvent.com

Gro Hjellum has more than 25 years of experience within research & development and operations in the pharmaceutical and biotech industry, ranging from analytical sciences, quality control and bio-analysis from preclinical product development through to regulatory approval of products. Prior to joining Oncoinvent, Gro worked for Nycomed/GE-Healthcare and Algeta/Bayer. She has a strong background in radiopharmaceutical product development and technology transfer to contract manufacturers in Norway as well as to US and Japan. Ms. Hjellum holds an MSc degree in radiochemistry from the University of Oslo.

 

Kristine Lofthus

Chief Production Officer

lofthus@oncoinvent.com

Kristine Lofthus has more than 15 years experience with the manufacturing of pharmaceuticals. Her main field of expertise is the manufacturing of aseptic and terminally sterilized injectables, and in particular radiopharmaceuticals. This experience includes production and production management, quality assurance and the certification and release of batches. She was previously licensed as a Qualified Person. Kristine holds a cand. pharm. degree (M.Sc.) from the University of Oslo, a certificate of Advanced Studies (CAS) in Radiopharmaceutical Chemistry/Radiopharmacy from Eidgenössische Technische Hochschule Zürich and is a licensed Qualified Person at Oncoinvent AS

Sara Westrøm

Chief Scientific Officer

westrom@oncoinvent.com

Dr. Sara Westrøm has more than 10 years of experience in radiopharmaceutical research and development and has been involved in the Radspherin® program from its inception. Since joining Oncoinvent in 2013, she has contributed to the advancement of Radspherin® from early research and preclinical development through clinical evaluation and broader scientific and strategic support of the program.

Dr. Westrøm is one of the co-inventors of the core Radspherin® patent. She holds an MSc in Nanotechnology from the Norwegian University of Science and Technology and completed an industrial PhD at the University of Oslo focused on the development of Radspherin®.

.

Anne-Kirsti Aksnes

Chief Clinical Officer

Dr. Anne-Kirsti Aksnes is a multi-disciplinary clinical research professional with more than 20 years of experience within clinical research and development in the pharmaceutical and biotech industry.  Dr. Aksnes has a strong knowledge of all aspects of clinical development and operations and a broad and reputable experiences with clinical studies in all phases (I-IV).  She is a physiologist by training with a Medical Doctorate Degree (PhD) from Karolinska Institute in Sweden.  Dr. Aksnes has held multiple senior positions including VP Clinical Development at Targovax ASA and Director of Clinical Research at G.E. Healthcare.  Dr. Aksnes also held the position of VP Clinical Development at Algeta ASA and was responsible for the clinical development of Xofigo, a product that has gone on to become the world’s most successful and largest selling radiopharmaceutical.

 

Anne Cecilie Alvik

Board member / Employee Representative

Worked at Oncoinvent AS since 2019 as Senior Quality Assurance Officer and Qualified Person (QP).

Have a cand. pharm. degree (M.Sc.) from the University of Tromsø, a certificate of Advanced Studies (CAS) in Radiopharmaceutical Chemistry/Radiopharmacy from Eidgenössische Technische Hochschule Zürich.

Has worked in pharma industry for 16 years and with radiopharmaceuticals for 10 years.

Has worked in Pharmacies for 7 years in various functions including leading positions.

Kaja Tunhøvd Johansen

Head of Quality Control

johansen@oncoinvent.com

Kaja Tunhøvd Johansen has six years of experience from the Quality Control department at Oncoinvent as Quality Control Scientist. She has strong expertise in analytical methods and solid experience in establishing and maintaining compliant procedures that ensure data integrity and process reliability within pharmaceutical laboratory operations.
 
Prior to joining Oncoinvent, Kaja completed a master’s degree in Chemical Engineering and Biotechnology (M.Sc.) at the Norwegian University of Science and Technology (NTNU) in Trondheim.

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.